Vanguard (VHT) vs VanEck (PPH): Which Healthcare ETF Is the Better Buy?

The article compares Vanguard Health Care ETF (VHT) and VanEck Pharmaceutical ETF (PPH), highlighting VHT’s much lower expense ratio of 0.09% versus 0.36% for PPH, along with broader diversification across 411 holdings versus 26. PPH offers a higher trailing 12-month dividend yield of 2.06% and stronger 1-year return of 21.9% versus 18.2% for VHT, but also carries higher concentration risk. The author concludes VHT is the better long-term hold due to lower fees, smaller drawdown, and wider healthcare exposure.

Analysis

The key market signal is not simply “cheap vs expensive,” but whether the healthcare sleeve is being used as a beta proxy for a narrow megacap pharma bet. VHT’s broader basket should dampen idiosyncratic single-name shocks and reduce path dependency; PPH’s outcome is increasingly hostage to a few obesity/GLP-1 leaders, which means the fund can outperform hard in momentum phases and underperform just as violently if leadership narrows or earnings expectations reset. That concentration also makes PPH more vulnerable to factor crowding: if the market rotates away from duration-like defensive growth, its top-weighted names can de-rate faster than a diversified healthcare basket.

The second-order winner is not necessarily the ETF issuer, but the underlying large-cap pharma franchises with visible capital return capacity. In a risk-off tape, VHT should attract allocators seeking defensive exposure without making a single-sector/ single-theme wager, while ABBV and JNJ benefit from investors treating healthcare as a ballast sleeve rather than a trade. NVS looks relatively more interesting on a relative basis if the market starts pricing in that PPH’s premium exposure is already reflected in the basket and the incremental upside from concentration is shrinking.

The contrarian point is that PPH’s recent outperformance may be backward-looking and mechanically driven by one dominant winner rather than a durable sector-wide regime shift. If GLP-1 enthusiasm stalls, pricing pressure in pharma reappears, or policy headlines hit drug makers, PPH’s higher fee load plus concentration will compound the drawdown. VHT is the better vehicle for the next 12-24 months if the goal is to own healthcare as an allocation, not as a single-theme momentum expression.

Key Decisions for Investors

• Rotate core healthcare exposure into VHT over PPH on a 6-12 month horizon; the setup favors lower fee drag and less single-name dependence if pharma breadth broadens, with downside cushioned by diversification.
• Pair trade: long VHT / short PPH for a 3-6 month mean-reversion trade; thesis is that PPH’s recent relative strength is over-owned and vulnerable to any GLP-1 or valuation reset.
• For stock selection inside the sleeve, favor JNJ and ABBV as higher-quality defensive compounders with capital return support; use 6-18 month horizon and avoid paying up for pure momentum exposure.
• If maintaining PPH exposure, hedge with an index call spread or partial short in a large-cap pharma proxy to cap concentration risk around catalyst windows over the next 1-2 quarters.
• Watch for sector rotation away from growth defensives; if rates back up or broad market breadth improves, trim PPH first because its top-heavy structure should underperform a diversified healthcare basket in that regime.